Creative Biolabs announced the launch of its enhanced lipid nanoparticle (LNP) conjugation platform—solving long‑standing challenges in nucleic acid delivery for gene therapy and RNA‑based therapeutics.
SHIRLEY, NY, April 24, 2026 /24-7PressRelease/ — As gene therapy and RNA medicines continue to expand across therapeutic areas, efficient and targeted delivery remains one of the industry’s most persistent bottlenecks. The newly released platforms from Creative Biolabs are designed to directly address these limitations by improving payload stability, enhancing biodistribution, and enabling precise tissue targeting—capabilities essential for translating laboratory breakthroughs into viable therapeutic candidates.
The upgraded custom formulation & conjugation platform consolidates a broad range of delivery technologies—including lipid nanoparticles, antibody‑RNA conjugates, GalNAc‑siRNA constructs, and exosome‑based carriers—into a unified, customizable workflow.
“Each formulation is optimized for encapsulation efficiency, targeting specificity, and in vivo performance, supported by comprehensive analytical characterization,” said a scientist at Creative Biolabs.
Next‑Level LNP Conjugation for Targeted Delivery
The LNP conjugation platform transforms conventional LNPs into programmable, ligand‑directed delivery vehicles. Through precise attachment of antibodies, peptides, aptamers, carbohydrates, or small molecules, the platform enables researchers to achieve refined targeting for CNS disorders, oncology programs, infectious disease vaccines, and gene‑editing applications.
“Our LNP formulation platform, validated through successful COVID-19 mRNA vaccines, offers versatile encapsulation of diverse nucleic acid cargoes including mRNA, siRNA, ASOs, and CRISPR components,” said a scientist at Creative Biolabs.
The platform incorporates microfluidic manufacturing, advanced surface‑coupling chemistries, and multi‑tier quality control to ensure reproducibility from early feasibility studies through preclinical scale‑up.
Early Customer Feedback
Early adopters of the upgraded platforms have reported measurable improvements in development efficiency and targeting performance.
“Creative Biolabs helped us overcome a delivery challenge we had been struggling with for months,” said Dr. E.K., Chief Scientific Officer at a biotechnology company developing siRNA therapeutics. “Their conjugation strategy not only improved our targeting efficiency but also delivered consistent batches that accelerated our preclinical timeline.”
Professor A.T., whose team is advancing a tumor‑targeted RNA therapy, noted, “The site‑specific antibody‑LNP conjugation significantly enhanced our binding affinity to tumor cells. It gave us the confidence to move forward with in vivo studies sooner than expected.”
Frequently Asked Questions
•Can multiple ligands be conjugated to a single LNP?
Yes. The platform supports multi‑ligand configurations for complex targeting strategies.
•Does conjugation affect LNP stability or encapsulation efficiency?
Conjugation workflows are designed to maintain structural integrity and high encapsulation efficiency.
•Are the services compatible with GMP‑aligned development?
Yes. Research‑grade materials follow cGMP‑compliant standards suitable for preclinical and IND‑enabling studies.
Learn more, please visit https://www.creative-biolabs.com/gene-therapy/.
About Creative Biolabs
Creative Biolabs is a global biotechnology solutions provider specializing in gene therapy development, nucleic acid formulation, and advanced bioconjugation chemistry. With extensive expertise in LNPs, antibody‑RNA conjugates, GalNAc systems, and other delivery technologies, the company delivers custom, scalable solutions that support therapeutic innovation from early research through preclinical advancement.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
